About
FibroGen (China) Pharmaceutical Technology Development Co., Ltd. is a Beijing-based biopharmaceutical company focused on the research and development of first-in-class innovative drugs, including their novel HIF-prolyl hydroxylase inhibitor Roxadustat for treating anemia associated with chronic kidney disease.
Explore FibroGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.